SLXN
Biomotion Sciences Ordinary Shares
NASDAQ: SLXN · HEALTHCARE · BIOTECHNOLOGY
$0.61
-3.00% today
Updated 2026-04-30
Market cap
$2.60M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-8.96
Dividend yield
—
52W range
$0 – $22
Volume
0.1M
Biomotion Sciences Ordinary Shares (SLXN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2012 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | $25000.00 | $14000.00 |
| Gross profit | — | — | — | — | — | $-25000.00 | $-14000.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | — | — | — | $3.23M | $3.71M | $5.82M | $7.14M |
| SG&A | — | — | — | $577000.00 | $928000.00 | $6.73M | $4.49M |
| Operating income | — | $-195860.00 | $-943933.00 | $-3.86M | $-4.68M | $-12.57M | $-11.63M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | — | $-195860.00 | $-755000.00 | $-3.80M | $-4.64M | $-16.48M | $-11.62M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-953000.00 | $-196000.00 | $-943933.00 | $-3.86M | $-4.68M | $-16.50M | $-11.63M |
| Interest expense | — | — | — | $85000.00 | $9000.00 | $52000.00 | $13000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | $-195860.00 | $-755218.00 | $-3.21M | $-4.94M | $-16.44M | $-11.91M |
| Net income growth (YoY) | — | — | -285.6% | -325.7% | -53.7% | -232.7% | +27.6% |
| Profit margin | — | — | — | — | — | — | — |